News|Articles|March 31, 2026

Strategic Alliances in Bioprocessing and R&D: A Q&A with Dr. Manisha Desai of Bristol Myers Squibb

Author(s)Feliza Mirasol, Manisha P. Desai

Bristol Myers Squibb’s Dr. Manisha Desai, senior vice president of Product Development, notes how strategic bioprocessing alliances accelerate drug development by integrating R&D and manufacturing to scale complex biologics and ensure reliability.

Strategic partnerships have become a cornerstone of modern drug development, driving innovation across increasingly complex therapeutic landscapes. BioPharm International® discussed how these alliances are reshaping bioprocessing, biopharma R&D, and manufacturing workflows with Manisha P. Desai, PhD, senior vice president of Product Development at Bristol Myers Squibb in a recent interview.

Related to this article

3D illustration of three golden spherical nanoparticles, one shown in cross-section to reveal a layered lipid shell, with a blue helical nucleic acid strand winding around them against a black background. | Image Credit: © Love Employee - stock.adobe.com

October 2nd, 2026

Novartis Licenses Abogen's mRNA-Encoded CD19xCD3 T-Cell Engager ABO2203 for Autoimmune Diseases

Novartis has secured an exclusive worldwide license to ABO2203, Abogen's investigational mRNA-encoded CD19xCD3 T-cell engager designed to produce the bispecific inside the body to reset B cells in autoimmune disease. The agreement also includes options on other programs built on Abogen's RNA platform.

Tablet, science team and people learning for cancer cure, help or medical development in laboratory. Training, investigation or research info with scientists in clinical trial for medicine internship | Image credit: © CoetzeeRising/peopleimages.com - © CoetzeeRising/peopleimages.com - stock.adobe.com

October 2nd, 2026

CaseBioscience Joins $7.3 Million ARPA-H Team on Cell Preservation

The 15-month project could let living cell therapies ship and store at room temperature, cutting cold-chain costs that limit patient access.

antibody-drug conjugation modality impacts overall therapeutic efficacy in brain tumors 3d rendering | Image credit: © Love Employee - © Love Employee - stock.adobe.com

October 2nd, 2026

AstraZeneca, Daiichi Sankyo, and Summit to Combine Datroway, Ivonescimab

A planned phase 3 trial will test the TROP2 ADC and PD-1/VEGF bispecific together in 1st-line triple-negative breast cancer.

A monoclonal antibody (mAb or moAb) is an antibody made by cloning a unique white blood cell. All subsequent antibodies derived this way trace back to a unique parent cell. Coronavirus. 3d render | Image credit: © Naeblys - © Naeblys - stock.adobe.com

October 1st, 2026

Regeneron, Sanofi Expand Alliance with $1 Billion Upfront, 4 Antibodies

Sanofi is paying Regeneron up to $8 billion to co-develop REGN20423 and 3 other long-acting antibodies beyond dupilumab (Dupixent).

Colorful chain of amino acids or bio molecules called proteins - 3d illustration | Image credit: © Christoph Burgstedt - © Christoph Burgstedt - stock.adobe.com

September 25th, 2026

Earendil Labs Inks $1.5 Billion Bispecific Antibody Pact with Genentech

Genentech is paying Earendil Labs $55 million upfront in a deal worth over $1.5 billion to develop bispecific antibodies for hard-to-treat cancers.

September 24th, 2026

BIIE Aims to Be a Global Immune Engineering Embassy

Dr Stephen Wilson, CEO of the Botnar Institute of Immune Engineering, describes Basel's collaborative ecosystem and a 3-year roadmap linking research to global clinical partners.

Science, teamwork and scientist with tablet in laboratory for communication, pharmaceutical review or planning. Employees, collaboration and technology | Image credit: © Coetzee/peopleimages.com - © Coetzee/peopleimages.com - stock.adobe.com

September 24th, 2026

InnoCare Signs Research Deal With Lilly Worth Up to $3.35 Billion

InnoCare will discover compounds against up to 5 targets for Lilly, backing a deal worth up to $3.35 billion in milestones.

FDA drug approval process, pharmaceutical regulatory compliance, food and drug administration certification, medical product approval concept, drug testing and approval | image credit: © Сергей Шиманович - © Сергей Шиманович - stock.adobe.com

October 5th, 2026

FDA Delays Novo Nordisk's Denecimig Over Facility Fixes

Manufacturing remediation, not efficacy or safety data, is delaying US approval of Novo's h+emophilia A therapy denecimig.